Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: A prospective randomized study

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 2, 2005, Pages 160-162

  Lund, Lars ^a   Ernst Jensen, Klaus Møller ^b   Tørring, Niels ^b   Nielsen, Jens Erik ^b  

^a VIBORG HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bleeding; Finasteride; Transurethral resection of the prostate

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MALE; OPERATION DURATION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC HYPERPLASIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 18244401630     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590510007694     Document Type: Article

References (15)

1. Emberton M. The hallmarks of BPH progression and risk factors. Eur Urol Suppl 2003;2:2-7.
2. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995;155:477-81.
3. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155:1251-9.
4. Roehrborn CG, McNicholas T. The management of prostatic obstruction: how to determine the best options? Eur Urol Suppl 2003;2:13-9.
5. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Writing Committee, the American Urological Association. Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-9.
6. Carlin BI, Bodner DR, Spinnak JP, Resnick MI. Role of finasteride in treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997;31:180-2.
7. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995;154:1779-82.
8. Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Agusta VE, Harpster LE. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159:1232-3.
9. McConnell JD, Stoner E. 5 alpha-reductase inhibitors. Adv Protein Chem 2001;56:143-80.
10. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000;55:684-7.
11. Pareek G, Shevchuk M, Armenakas A, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20-3.
12. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-91.
13. Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group J Urol 1992;147:1298-302.
14. Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002;168:2024-6.
15. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992;70(1 Suppl):291-301.